Gilead Sciences Inc
NASDAQ:GILD
Gilead Sciences Inc
Current Portion of Long-Term Debt
Gilead Sciences Inc
Current Portion of Long-Term Debt Peer Comparison
Competitive Current Portion of Long-Term Debt Analysis
Latest Figures & CAGR of Competitors
Company | Current Portion of Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Gilead Sciences Inc
NASDAQ:GILD
|
Current Portion of Long-Term Debt
$3.7B
|
CAGR 3-Years
18%
|
CAGR 5-Years
8%
|
CAGR 10-Years
7%
|
|
Abbvie Inc
NYSE:ABBV
|
Current Portion of Long-Term Debt
$10.2B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
45%
|
CAGR 10-Years
88%
|
|
Amgen Inc
NASDAQ:AMGN
|
Current Portion of Long-Term Debt
$4B
|
CAGR 3-Years
37%
|
CAGR 5-Years
1%
|
CAGR 10-Years
5%
|
|
Moderna Inc
NASDAQ:MRNA
|
Current Portion of Long-Term Debt
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Current Portion of Long-Term Debt
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Current Portion of Long-Term Debt
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Gilead Sciences Inc's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
3.7B
USD
Based on the financial report for Mar 31, 2024, Gilead Sciences Inc's Current Portion of Long-Term Debt amounts to 3.7B USD.
What is Gilead Sciences Inc's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 10Y
7%
Over the last year, the Current Portion of Long-Term Debt growth was 61%. The average annual Current Portion of Long-Term Debt growth rates for Gilead Sciences Inc have been 18% over the past three years , 8% over the past five years , and 7% over the past ten years .